The pharmacokinetics of ampicillin and sulbactam, a new I-lactamase inhibitor, were investipted in 16 patients undergoing prosthetic cardiac valve insertion. The combination of 2 g of ampidilIn and g of sulbactam was administered as perioperative prophylaxis intravenously over 3 to 6 days. Several serum pharmacokinetic parameters were similar for the two drugs after three intravenous doses were given to p1itents following surgery. The half-lives of eliminatonof ampicillinand sulbactam were 79 4.9 and 88 5.9 min, the volumes of distribution were 15.6 1.4 and 17.7 1.2 liters/70 kg, and the total plasma clearances were 144.4 t 14.5 and 147.2 14.5 m/min, respectively. The peak concentrations of ampiciln and sulbactan in serum were calculated to be 134.3 t 1.3 and 58.3 ± 1.2 pg/ml, respectively. Ampicillin and sulbam rapidly penetrated from the blood into various tissues collected durng heart surgery, such as sternum, pericardium, myocardium, and endocardinm. The concentrations of ampicillin in tissue ranged from 17.8 4 9.9 to 50 *±29.5 ,ug/g, and those of sulbactam in tissue ranged from 8.8 6.2 to 19.6 ± 10.1 gLg/g. The concentrations of ampicillin and sulbactam in serum and tissue also apparently exceded the MICs gainst most B-lactamaseproducing-bacteria usually involved in-postoperative wound infections and prosthetic valve endocarditis. The ratio of the two compounds was approximately 2:1 in serum and in the various tissues affected by the operation. The pharmacokinetics of ampicillin and sulbactam in serum and investigated tissues sugest that the combination of the two ,B-lactams will be effective in the perioperative prophylaxis of patients undergoing heart surgery.
Experience in cardiac surgery has demonstrated that such surgery carries a significant risk of infection when antibiotics are not administered perioperatively. Infection of sternal wounds, endocarditis, pneumonia, and bacteremia can all occur postoperatively (4) . Prophylaxis with antibiotics, usually of the ,B-lactam group, is therefore almost routine, and this is also the case with the implantation of prosthetic heart valves (2) . It has been demonstrated that the efficacy of ampicillin is markedly improved by the addition of sulbactam, a new semisynthetic 3-lactamase inhibitor, and this combination seems particularly indicated for use in perioperative prophylaxis in cardiac surgery, because of its-favorable tolerance and antibacterial spectrum.
We have therefore evaluated the pharmacokinetics of ampicillin and sulbactam during the perioperative period in patients undergoing heart surgery.
MATERIALS AND METHODS
Patients. Sixteen subjects (seven female and nine male) undergoing heart surgery, mainly insertion of prothetic heart valves, were included in the study after informed written consent had been given. Their mean age was 59.4 ± obtained from analyses of aliquots of the same sample (4 pug of sulbactam per ml of serum) on 3 successive days. Ampicillin assay. The concentrations of ampicillin were analyzed in triplicate in the same samples by a microbiological cylinder plate technique with Sarcina lutea ATCC 9341. Ampicillin standards for the serum samples were prepared in pooled noninhibitory human serum and ranged from 0.0125 to 437.4 ,ug/ml. The intraday and interday coefficients of variation for the serum standards were .1.6% in the intermediate range of the reference curves. The supernatant fluids of the tissue samples were diluted with phosphate buffer (pH 7.0) to yield final dilutions of 1/12 and 1/36. One of the samples was spiked with ampicillin. All samples were assayed against an ampicillin standard prepared in phosphate buffer (pH 7.0) at 0.033 and 0.011 pugIml, with a standard 6 by 6 Latin square. After determination of the relative potencies of the two samples, the percent recovery in the spiked tissue was calculated (mean recovery, 99.6% + 3.5%; n = 67). The bioassays of ampicillin were not affected by the presence of sulbactam (12) .
Pharmacokinetic analysis. The TOPFIT computer program (1) was used to derive serum pharmacokinetic parameters All data reported in Table 1 are based on the fitted curves.
RESULTS
The concentrations of ampicillin and sulbactam in serum after intravenous administration to patients undergoing heart surgery are shown in Fig. 1 . The pharmacokinetic parameters were calculated from the serum data obtained after three infusions of the drug combination at 8-h intervals over the course of 1 day (Table 1) . After a 15-min infusion of 2 g of ampicillin and 1 g of sulbactam, peak concentrations in serum were calculated to be 134. postoperatively. The leucocyte counts of the patients were slightly increased on the second day after the operation but returned to the normal range 2 days later. Three days after the completion of the ampicillin-sulbactam prophylaxis and 6 days after the operation, infection of the sternum with Staphylococcus aureus was observed in a single patient. The infection was preceded by bursting of a circular suture in the area of the sternotomy.
No adverse drug reactions were noted in any patient during the perioperative prophylaxis.
DISCUSSION
Infections after heart surgery represent a substantial risk that can compromise the quality of the surgical procedure and finally the success of the operation (9). In the choice of an antibiotic for perioperative prophylaxis, not only the antimicrobial spectrum and tolerance but also the pharmacokinetic properties of the drug are important. The total distribution of the active substance, excretion, and concentrations in various tissues in the area of the operation are all significant. The serum pharmacokinetics of ampicillin and sulbactam were similar after three intravenous combination doses to patients undergoing heart surgery ( Fig. 1 and Table  1 ). The volumes of distribution were ca. 15.6 and 17.7 liters for ampicillin and sulbactam, respectively, suggesting that both drugs are widely distributed in extracellular fluid and tissues. Analyses of the samples indicated that ampicillin and sulbactam did indeed rapidly penetrate from the blood into the various tissues collected during heart surgery ( Table  2 and Fig. 2 to 5 ). It is noteworthy that ampicillin and sulbactam were able to pass not only into cardiac tissue, such as the pericardium, myocardium, and endocardium (Fig. 3, 4 , and 5), but also into the sternum within a few minutes (Fig. 2) . The ratio of the two substances in the intravenous dose was 2:1, and this ratio was largely maintained in serum and in the various tissues affected by the operation. This finding is of the utmost importance, as the presence of sulbactam is necessary to inhibit the degradation of ampicillin by P-lactamases. Sufficiently high concentrations of sulbactam must be present at the site of infection together with ampicillin. Analyses of ampicillin and sulbactam in samples taken from 16 patients during heart surgery revealed concentrations in serum and tissue that are effective even against aerobic and anaerobic bacteria that produce ,-lactamases. The bacteria involved in postoperative infections following heart surgery, such as S. aureus, S. epidermidis, or streptococci (4, 7) , are inhibited by ampicillin-sulbactam (MICs for 90% of strains) in the range of 0.5 to 4 ,ug of ampicillin per ml (6) . These MICs were substantially exceeded by the concentrations of ampicillin in the various tissues and serum from all 16 heart surgery patients investigated. On the basis of our pharmacokinetic data, both compounds attained therapeutically effective concentrations in serum, in the various cardiac tissues, and even in the prophylaxis, the group of 15 patients was too small to assess the tolerance of the combination in patients undergoing heart surgery. In addition, our assessment of the pharmacokinetic data is supported by the efficacy in a larger number of patients of 2 g of ampicillin and 1 g of sulbactam against systemic infections involving some tissues investigated in the present study. Thus, the observed penetration of ampicillin and sulbactam into the sternum provides an explanation for the successful treatment with this combination of patients suffering from bone infections (11) . Other clinical studies have clearly demonstrated the efficacy of ampicillinsulbactam in the prophylaxis of infectious complications in several types of surgical procedures, such as gastrointestinal, gynecological, or breast surgery (3, 5, 10) . In conclusion, the pharmacokinetic data and clinical results strongly suggest that the combination of ampicillin and sulbactam is generally effective in perioperative prophylaxis for patients undergoing heart surgery and should provide adequate protection. 
